ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

Funding Opportunities

February 7, 2003

2006 demonstration project to pay $23 per office visit.

November 4, 2005

In Brief: Hammond Resigned As ACS Officer; Wykoff Slated To Direct FDA Special Populations Office

November 20, 1992

Breast Cancer Incidence Reduced 45% In Tamoxifen Arm Of BCPT; Trial Unblinded

April 10, 1998

NCAB Members Flay NIH Proposals To Kill Cancer Program, Strip Board An NCI Of Special Authority

January 25, 1980

Evidence “Weak” Linking EMFs, cancer

June 25, 1999